Tumour response · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
2 findings from 1 review
Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
It is very uncertain whether chemmotherapy combined with biological therapy changes tumour response rate compared with chemotherapy (very low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
4 findings from 1 review
OR 1.72 [1.24, 2.4]
10 studies · 1266 participants
Low
OR 1.53 [0.93, 2.5]
6 studies · 756 participants
Low
OR 2.18 [1.25, 3.8]
3 studies · 345 participants
Low
Show 1 more finding
Tumour response · people with advanced gastric cancer
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
4 findings from 1 review
OR 1.37 [1.03, 1.83]
9 studies · 1820 participants
Moderate
OR 1.03 [0.71, 1.5]
4 studies · 525 participants
Moderate
OR 1.83 [1.45, 2.32]
4 studies · 1235 participants
High
Show 1 more finding
Tumour response · people with advanced gastric cancer
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Oxaliplatin probably leads to higher tumour response compared with the same regimen including cisplatin (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review